TACE. PVE. HIFU sequential evaluation of the treatment of primary liver cancer

Abstract

Objective To study TACE. PVE. HIFU clinical efficacy of sequential treatment of primary liver cancer and methods. Methods 60 patients with primary liver cancer in our hospital were randomly divided into two groups: treatment group 30: TACE. PVE. HIFU sequential therapy; control group, 30 cases: give transcatheter chemoembolization ( TACE ). After treatment, to evaluate the clinical efficacy analysis, all patients were followed up for 3 years observation of survival, and analysis of relevant factors. Results 60 patients with primary liver cancer, total effective rate was 53.3% in 16 cases, 7 cases of the control group, 23.3% clinical efficacy in treatment group significantly better than the control group. Two groups of patients with primary liver cancer, its treatment of 3-year survival rate was 46. 7% for the 14 cases, while 8 patients accounted for 26. 7%, significantly higher survival rate in treatment group and control group. 60 cases of primary liver cancer patients with different grades of liver function after treatment Child: 6-month survival rate of 85.0% in 51 cases, 43 patients 1 year survival rate of 71.7% , 2-year survival rate of 32 cases of 53.3% , 3 years 36. 7% survival rate of 22 cases. Child A liver function have a higher survival rate. Conclusion TACE. PVE. HIFU sequential treatment of primary liver cancer in the application should complement each other to complete the purpose of killing cancer cells. Key words: Hepatocellular carcinoma; TACE; PVE; HIFU; Efficacy evaluation; Survival rate